Alembic Pharmaceuticals Limited
Pharmaceuticals
Annual Returns


Cumulative Returns and Drawdowns


Ownership

Margined

AI Summary
asof: 2026-09-16
Alembic Pharmaceuticals (APLLTD) — Recent Developments Summary
1. Headwinds and Challenges
- Employee benefit obligations arose from the revised
definition of wages under the Labour Codes, weighing on costs.
- A write-down on assets of the Sikkim manufacturing
facility was recognised, with the facility classified as held
for sale under Ind AS 105.
- Material consumption rose sharply — up 52% YoY and
17% QoQ in Q1 FY27 — alongside a gross margin decline to 71% from 76% a
year earlier.
- Profit growth lagged revenue growth: while revenue
rose 26% YoY, PAT grew only 12% YoY, and PAT declined 15% QoQ.
- India Branded Business growth was modest at 7% YoY,
with a longer-term revenue CAGR of just 6%, and the company holds only a
1.1% share of the Indian pharma market.
- R&D spend is rising (9% of revenue in Q1 FY27,
up 29% YoY), reflecting planned strategic expansion in the US branded
business and a peptide-focused pipeline, which pressures near-term
margins.
- The investor presentation’s safe harbour statement flags inherent
risks including regulatory approvals, product safety and
efficacy concerns, healthcare reforms, currency and interest rate
fluctuations, raw material availability, and market
acceptance.
- Governance-related dissent appeared at the AGM: the
resolution to appoint Mr. Sujit Jaysukh Bhayani as an Independent
Director (Item 4) saw 34.85% of public institution votes against, and
6.92% of total votes polled against — the only resolution with
meaningful opposition. The director re-appointment resolution (Item 3)
also drew 0.28% votes against.
2. Tailwinds and Growth Prospects
- Q1 FY27 was a strong quarter: revenue from
operations rose 26% YoY to Rs. 2,150 Cr; EBITDA pre-R&D rose 21% YoY
to Rs. 523 Cr (24% margin); PAT was Rs. 173 Cr, up 12% YoY.
- US Formulation grew 49% YoY to Rs. 778 Cr, driven
by key product launches and volumes, with 7 launches in the quarter and
10 ANDA approvals (including 2 tentative).
- Ex-US Generics grew 17% YoY to Rs. 383 Cr, with
partnerships in Europe, Canada, Australia, Brazil, Chile and South
Africa, plus a JV in Canada and new subsidiaries in Thailand, the
Philippines and Germany.
- API business grew 33% YoY to Rs. 346 Cr on strong
order book and demand; 3 US DMFs filed in Q1 FY27, taking cumulative
filings to 152.
- India Branded Business reached Rs. 642 Cr, with
robust growth in Gynaecology, Gastrology and Ophthalmology; 3 new
products launched; Animal Health grew 24% (23% in the quarter) with a
22% CAGR.
- Pipeline visibility: 15+ US product launches
expected in FY27; 279 cumulative ANDA filings, 244 approvals and 185
products launched; Pivya soft launch completed with encouraging
response, plus Nuvessa addition.
- Regulatory clearances: F3 Karkhadi received its EIR
on 13 May 2026 (certification April 2026); the Vadodara bioequivalence
facility cleared an unannounced USFDA inspection (31 Aug–10 Sep 2026)
with no Form 483 observations.
- Sustainability positioning: one of 10 Indian pharma
companies with SBTi-approved targets; net zero by 2050, water neutrality
by 2027, 24 MW solar park commissioned.
- Consistent dividend payout and ongoing investor
engagement (one-to-one meetings with Dolat Capital, Equirus, 360 ONE,
ICICI Securities, Ashmore, HSBC, BOB Capital, Nirmal Bang and Yes
Securities on 1–2 September 2026).
3. Key Risks
- Regulatory and inspection risk across USFDA- and
WHO-approved facilities, though recent audits (F3 EIR, Vadodara BE
inspection) were clean.
- Product concentration and competitive pressure in
the US generics portfolio, with pipeline dependent on timely approvals
and launches.
- Margin pressure from rising material costs, R&D
intensity, and expansion into US branded business.
- Execution risk in newer markets (Canada JV,
Thailand, Philippines, Germany) and in the peptide/specialty
pipeline.
- Macro and currency exposure across international
operations, as flagged in the safe harbour statement.
- One-off cost items such as Labour Code wage
revisions and the Sikkim facility write-down.
- Shareholder dissent risk evidenced by the
significant minority vote against the Independent Director
appointment.
Broker Narrative
Early reports framed APLLTD as a US-generics laggard, with price
erosion, high base, product-mix pressure, and rising opex as key
headwinds, while domestic, ex-US, API, and specialty growth were the
offsets. By the last report, the US business had become a positive
surprise (US generics +49% YoY, limited-competition launches), but
persistent gross margin contraction, higher depreciation/amortization,
domestic acute weakness, and debt kept the call at Neutral with limited
upside. The narrative shifted from US demand concerns to margin/cost
absorption and India branded performance, while operating leverage
improved.
Fears that came true
- The early fear of inferior product mix leading to YoY gross margin
contraction materialized: the last report showed gross margin down 500bp
YoY to 71.2%, and this margin pressure accompanied multiple negative
actual returns/DISAPPOINTMENT outcomes (e.g., Aug-2024 Buy +11.0%
predicted vs -19.4% actual).
- The early fear of incremental operating expenses from new
facilities/businesses materialized as higher depreciation and tax rates,
with ~70-75% of depreciation increase from amortizing intangibles for
the US branded business, offsetting improved US traction and weighing on
returns (e.g., 2025-08-05 Neutral +4.5% predicted vs -12.3%
actual).
Optimism that failed
- The expectation of sustained domestic formulations growth (9% YoY
and 10-12% FY24 guidance) did not hold: by 1QFY27 the domestic acute
segment declined 2.1% YoY and remained a drag on the India branded
business.
- The management guidance of ~15% EBITDA margin for FY24 did not
materialize as a durable margin improvement; management later reiterated
FY27 EBITDA margin dilution of ~150bps alongside the 500bp gross margin
contraction.
Broker Timeline
7 broker calls · 2023-05-07 to 2026-01-05
CNBC-TV18: ratings, targets and commentary
No recorded CNBC-TV18 statements for this ticker.
Management comments
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.
🐞